Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Benitec Biopharma (BNTC) Interest & Investment Income (2019 - 2025)

Benitec Biopharma (BNTC) has disclosed Interest & Investment Income for 7 consecutive years, with $3.3 million as the latest value for Q2 2025.

  • Quarterly Interest & Investment Income rose 257.17% to $3.3 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Jun 2025, up 512.39% year-over-year, with the annual reading at $3.3 million for FY2025, 263.5% up from the prior year.
  • Interest & Investment Income hit $3.3 million in Q2 2025 for Benitec Biopharma, up from $823000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $3.3 million in Q2 2025 to a low of -$11000.0 in Q4 2021.
  • Historically, Interest & Investment Income has averaged $354000.0 across 5 years, with a median of -$5000.0 in 2023.
  • Biggest five-year swings in Interest & Investment Income: tumbled 900.0% in 2022 and later skyrocketed 20675.0% in 2025.
  • Year by year, Interest & Investment Income stood at -$11000.0 in 2021, then grew by 18.18% to -$9000.0 in 2022, then skyrocketed by 33.33% to -$6000.0 in 2023, then soared by 13816.67% to $823000.0 in 2024, then soared by 299.27% to $3.3 million in 2025.
  • Business Quant data shows Interest & Investment Income for BNTC at $3.3 million in Q2 2025, $823000.0 in Q1 2025, and $823000.0 in Q4 2024.